Transcriptomics Global Market Report 2025

The transcriptomics market size has grown strongly in recent years. It will grow from $6.51 billion in 2024 to $7.06 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth observed in the past can be attributed to an increasing emphasis on personalized medicine, a rising prevalence of cancer, the incorporation of genomics in clinical diagnostics, the expansion of ribonucleic acid sequencing, and a growing demand for biomarker discovery.

The transcriptomics market size is expected to see strong growth in the next few years. It will grow to $9.65 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The expected growth in the forecast period is driven by the rising adoption of single-cell ribonucleic acid sequencing, the increasing integration of spatial transcriptomics, the growing demand for multiomics approaches, a heightened focus on early disease detection, and greater awareness of the significance of non-coding ribonucleic acids. Key trends for the forecast period include advancements in next-generation sequencing (NGS) technologies, innovations in spatial transcriptomics, improvements in bioinformatics tools, the integration of machine learning in transcriptomics, and progress in real-time transcriptomic analysis technologies.

The growing adoption of personalized medicine is expected to drive the growth of the transcriptomics market in the future. Personalized medicine involves customizing treatments based on an individual’s genetic makeup, lifestyle, and environmental factors. This approach is gaining traction due to advancements in genetic sequencing, which allow for treatments tailored to a person’s genetic profile for greater effectiveness. Transcriptomics helps uncover unique gene expression patterns, enabling personalized treatments that are more effective, reduce side effects, and support early disease diagnosis. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to just six in 2022. As a result, the increasing adoption of personalized medicine is contributing to the growth of the transcriptomics market.

Companies in the transcriptomics market are focused on developing innovative products such as single-cell spatial panels to gain deeper insights into cellular functions and disease mechanisms. Single-cell spatial panels analyze gene expression at the individual cell level while preserving the cells’ positions within the tissue. These panels combine single-cell transcriptomics with spatial data, providing insights into both cellular activity and tissue structure. For instance, in February 2024, NanoString Technologies launched the CosMx 6,000 plex RNA Assay, the first commercial single-cell spatial panel capable of measuring over 6,000 RNA targets across nearly all human biological pathways. This breakthrough, designed for use with the CosMx Spatial Molecular Imager (SMI), enables researchers to profile genes at single-cell and subcellular resolution with high accuracy and advanced cell segmentation.

In July 2024, Illumina, Inc., a U.S.-based provider of DNA sequencing and array-based technologies, acquired Fluent BioSciences for an undisclosed amount. This acquisition aims to enhance Illumina’s multiomics capabilities by integrating Fluent’s innovative, scalable single-cell technology, which eliminates the need for complex and expensive equipment. This enables faster, more cost-effective, and comprehensive discoveries in genomics and cell biology. Fluent BioSciences specializes in single-cell analysis technology, a key method in transcriptomics that allows researchers to profile gene expression at the individual cell level.

Major players in the transcriptomics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Becton Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Takara Bio Inc., 10x Genomics Inc., Oxford Nanopore Technologies plc, Genewiz Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Singleron Biotechnologies, SCIEX, CD Genomics Inc., Parse Biosciences Inc., Lexogen GmbH, LC Sciences LLC, and Arraystar Inc.

North America was the largest region in the transcriptomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in transcriptomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the transcriptomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Transcriptomics is the study of all ribonucleic acid (RNA) transcripts generated by the genome within a specific cell, tissue, or condition. It aids in deciphering gene expression patterns and regulatory processes, revealing how they change in response to diseases or environmental influences. This field provides valuable insights into cellular functions and disease mechanisms. Transcriptomics plays a key role in biomarker discovery, identifying therapeutic targets, and advancing personalized medicine.

The primary categories of transcriptomics include instruments, consumables, software, and services. Instruments are vital in transcriptomics as they allow for the precise analysis of gene expression through high-throughput sequencing, amplification, and RNA detection. Various technologies are employed, such as microarrays, real-time quantitative polymerase chain reaction, and sequencing technologies. These tools are used for multiple applications, including diagnostics, disease profiling, drug discovery, and others, and are utilized by a wide range of end-users, such as academic and research institutions, pharmaceutical companies, biotechnology firms, and more.

The transcriptomics market research report is one of a series of new reports that provides transcriptomics market statistics, including the transcriptomics industry global market size, regional shares, competitors with the transcriptomics market share, detailed transcriptomics market segments, market trends, and opportunities, and any further data you may need to thrive in the transcriptomics industry. This transcriptomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The transcriptomics market consists of revenues earned by entities by providing services such as voice gene expression analysis, ribonucleic acid sequencing, bioinformatics solutions, and data interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The transcriptomics market also includes sales of RNA extraction kits, library preparation kits, and cDNA synthesis kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.